Before 2021, European life sciences was a niche sector with a limited pool of operators. Now, the landscape has changed. Across the continent, and in the United Kingdom in particular, a “triple helix” has emerged between world-class academia and the commercialisation of research; high levels of venture capital investment; and transnational aspirations to grow countries’ standings in science and technology.

The result has been infectious — both in respect of the rapid growth of occupational demand, but also in terms of the institutional capital that has followed. As the most advanced market outside of the United States, investors see the potential for once overlooked European markets to play catch-up. Appetite for the European market has been enhanced by the COVID-19 crisis, which further highlighted both the strength of the UK ecosystem, as well as the relative resilience of technical real estate to homeworking trends.

Investment in Europe has been underpinned